For patients with clearly defined adenocarcinoma differentiation, patients with poor morphological differentiation and immunophenotypic tendency toward adenocarcinoma, patients with large cell carcinoma as well as patients with NSCC, NOS, the testing of EGFR, ALK, ROS1 and other tumor driver genes should be performed to help find probable therapeutic targets. This evidence concerns the gene EGFR and neoplasm.